Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect

Thrombosis and Haemostasis

Volumn 83, Issue 5, 2000, Pages 688-692

  Dangas, George ^a,b   Smith, Donald A ^a   Unger, Allen H ^a   Shao, John H ^a   Meraj, Perwaiz ^a   Fier, Carl ^a   Cohen, Adam M ^a   Fallon, John T ^a   Badimon, Juan J ^a   Ambrose, John A ^a,c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

Endothelium; Lipids; Platelet; Thrombus

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; THROMBOGENICITY; TIME;

EID: 0034116167     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613893     Document Type: Article

References (23)

1. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 1998; 339: 1349-57.
2. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease: The Scandinavian Simvaslatin Survival Study (4S). Lancet 1994; 344: 1383-9.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langerdorfer A, Stein EA, Kruyer W, Gotto AM for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998; 279: 1615-22.
4. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Move LA, Rouleau JL, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-6.
5. Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzha J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
6. Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999; 33: 1305-7.
7. Rosenson RS, Tagney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA 1998; 279: 1643-50.
8. Dangas G, Badimon JJ, Smith, DA, Unger, AH, Levine, D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 5: 1294-304.
9. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
10. Rauch U, Badimon JJ, Vorchheimer DA et al. Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: effect of simvastatin. J Am Coll Cardiol 1998; 31 (Suppl A): 194A.
11. Tsuda Y, Satoh K, Kitadi M. Effects of prevastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33.
12. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol 1996; 27 (Suppl A): 413A.
13. Morrissey JH, Macik BG, Neuenschwandcr PF, Comp PC. Quantification of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
14. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
15. Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition under dynamic flow conditions. Implications for a potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol 1998; 18: 1342-9.
16. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin atherosclerosis Intervention Program. Circulation. 1995; 92: 2419-25
17. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 1998; 97: 1440-5.
18. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995; 92: 2333-42.
19. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
20. Dangas G, Mehran R, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, Ambrose JA. Correlation between angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997; 29: 519-25.
21. Vanderkerchove Y, Baele G, dePuydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988; 50: 449-53.
22. Ridker PM, Vaughn DE, Stampfer MJ. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
23. Vorchheimer DA, Rauch U, Dandler, DA, Fuster V, Chesebro JA, Arslan B, Guzman IC, Palencia S, Badimon JJ. Statin therapy reduces blood thrombogenicity: evidence for an antithrombotic effect independent of LDL reduction. Circulation 1998; 17 (Suppl 1): 1-452 (Abstract).